secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2022-03-09T23:59:59+00:00
Accession:  0000950142-22-000983
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx CEO Javitt retires; Robert Besthof named interim CEO; narrows focus to US
-----------------------------------------------------------------------------

- Dr. Jonathan Javitt retired as CEO effective March 8, 2022; becomes Chief Scientist and remains on Board.
- Robert Besthof, Head of Operations, appointed Interim CEO; received 100,000 stock options at $2.61/share.
- Javitt consulting agreement: $250,000 upfront plus $75,000/month for one year.
- Company narrows geographic focus to US; ceasing efforts in Georgia and Caucasus due to geopolitical environment.
- Continues development of ZYESAMI for Critical COVID-19 and psychiatric pipeline including NRX-101.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/0000950142-22-000983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/eh220233089_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-000983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer